- Home
- HKIT vs CVKD Comparison
HKIT vs CVKD Comparison
Compare HKIT & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HKIT
- CVKD
- Stock Information
- Founded
- HKIT 1996
- CVKD 2022
- Country
- HKIT China
- CVKD United States
- Employees
- HKIT N/A
- CVKD N/A
- Industry
- HKIT Computer Software: Prepackaged Software
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- HKIT Technology
- CVKD Health Care
- Exchange
- HKIT Nasdaq
- CVKD Nasdaq
- Market Cap
- HKIT 35.7M
- CVKD 31.5M
- IPO Year
- HKIT 2023
- CVKD 2023
- Fundamental
- Price
- HKIT $1.21
- CVKD $16.75
- Analyst Decision
- HKIT
- CVKD Strong Buy
- Analyst Count
- HKIT 0
- CVKD 1
- Target Price
- HKIT N/A
- CVKD $32.00
- AVG Volume (30 Days)
- HKIT 15.0K
- CVKD 22.8K
- Earning Date
- HKIT 04-29-2025
- CVKD 05-08-2025
- Dividend Yield
- HKIT N/A
- CVKD N/A
- EPS Growth
- HKIT N/A
- CVKD N/A
- EPS
- HKIT 0.04
- CVKD N/A
- Revenue
- HKIT $3,449,206.00
- CVKD N/A
- Revenue This Year
- HKIT N/A
- CVKD N/A
- Revenue Next Year
- HKIT N/A
- CVKD N/A
- P/E Ratio
- HKIT $31.55
- CVKD N/A
- Revenue Growth
- HKIT N/A
- CVKD N/A
- 52 Week Low
- HKIT $1.00
- CVKD $5.70
- 52 Week High
- HKIT $2.18
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- HKIT 46.40
- CVKD 49.23
- Support Level
- HKIT $1.20
- CVKD $14.10
- Resistance Level
- HKIT $1.25
- CVKD $17.39
- Average True Range (ATR)
- HKIT 0.03
- CVKD 1.57
- MACD
- HKIT -0.00
- CVKD 0.04
- Stochastic Oscillator
- HKIT 26.92
- CVKD 54.19
About HKIT Hitek Global Inc.
Hitek Global Inc is a provider of information technology consulting and solutions services. The company has two lines of businesses such as services to small and medium businesses, which consist of Anti-Counterfeiting Tax Control System tax devices, including Golden Tax Disk and printers, ACTCS services, and IT services; and services to large businesses, which include hardware sales and software sales. It generates revenues from hardware sales, software sales, IT services, and tax devices and services.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.